ReviewHaematologica2009
Blood cell activation in myeloproliferative neoplasms.
Review in Haematologica, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Procoagulant effect of phosphatidylserine-exposed blood cells, endothelial cells and extracellular vesicles in patients with aortic stenosis.Thrombosis journal · 2025Article
- Genomic classification and outcomes of young patients with polycythemia vera and essential thrombocythemia according to the presence of splanchnic vein thrombosis and its chronology.Annals of hematology · 2024Article
- Mass Cytometry Phenotyping of Human Granulocytes Reveals Novel Basophil Functional Heterogeneity.iScience · 2020Article
- Unexpected low expression of platelet fibrinogen receptor in patients with chronic myeloproliferative neoplasms: how does it change with aspirin?British journal of haematology · 2020Article
- JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation.The Journal of clinical investigation · 2018Article
- Expression of CD markers in JAK2Oncology reviews · 2018Article
- Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.Haematologica · 2017Article
- Article
- Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms.Blood cancer journal · 2011Article
- Pathophysiology of thrombosis in myeloproliferative neoplasms.Haematologica · 2011Article
- Splanchnic vein thrombosis, the onset manifestation in JAK positive Chronic Myeloproliferative Disorders Neoplasms.Journal of medicine and lifeArticle
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.